

Supplementary Table S6. Ongoing clinical trials in IBD with systemic MSC-based therapy (listed in chronological order)

Clinical Trial Identifier	Clinical Phase	Source	Registration year	Country	IBD patients	MHC context	Route of administration	Cells/kg of Body Weight; Number of Doses	Number of IBD Patients Enrolled	Follow-Up (Months)	Publication (Year)	Status	Included Control Group	Estimation date for completion	Age range (years)
2011-005966-39	II	NA	2012	Belgium	Refractory CD patients	NA	IV	NA	15				No		18-75
NCT01510431	NA	BM	2012	USA	Refractory CD patients	Allogeneic	IV	-2x10 ⁸ , 4 doses= 8x10 ⁸ every 3 days	NA	NA		No longer available	No	2020	18-70
NCT01914887	I/IIa	AD	2013	Spain	Early diagnosed and 5-ASA-resistant CU patients	Allogeneic	Local	60x10 ⁶ , 1 dose	8	3 months		Unknown status	No	Unknown status	>18
NCT02000362	I/IIa	UC	2014	Korea	Refractory CD patients	Allogeneic	IV	-5x10 ⁷ , 1 dose -1x10 ⁸ , 1 dose	24	1 month		Recruiting	No	Unknown	19-70
NCT02442037	I/II	UC	2015	China	UC patients	Allogeneic	IV	1x10 ⁶ /Kg, 3 doses= 3x10 ⁶ /Kg	30	6 months		Recruiting	Yes	Unknown	18-65
NCT02580617	I	AD	2015	Korea	Refractory CD patients	Allogeneic	IV	-5x10 ⁷ , 1 dose -7.5x10 ⁷ , 1 dose -10x10 ⁷ , 1 dose	9	1 month		Recruiting	No	2021	18-65
NCT03183661	I	AD	2016	Korea	CD patients	Allogeneic	IV	NA	9	36 months		Enrolling by invitation	No	2021	18-65
NCT02926300	I/IIa	UC	2016	Korea	Refractory CD patients	Allogeneic	IV	NA	24	28 months		Recruiting	No	2021	19-70
NCT03299413	I/II	Wharton Jelly	2017	Jordan	Early diagnosed UC patients	Allogeneic	IV	60x10 ⁶ , 2 doses= 120x10 ⁶	20	6 months		Active, not recruiting	No	2019	18-75
NCT03609905	I/II	AD	2018	China	Early diagnosed and 5-ASA, glucocorticoid or azathioprine-resistant CU patients	Allogeneic	Local	5x10 ⁷ , 2 doses= 10x10 ⁷	50	2 months		Recruiting	No	Unknown	18-65
NCT04548583	Ib/IIa	BM	2020	USA	Refractory CD patients	Allogeneic	Local	-150x10 ⁶ , 1 dose -300x10 ⁶ , 1 dose	24	24 months		Recruiting	Yes	2023	18-75
NCT04312113	I	AD	2020	USA	Refractory UC patients	Autologous	IA	-15x10 ⁶ , 1 dose -30x10 ⁶ , 1 dose	20	24 months		Recruiting	No	2022	18-65
NCT04543994	I/II	BM	2020	USA	Refractory UC patients	Allogeneic	Local	-150x10 ⁶ , 2 doses= 300x10 ⁶ -300x10 ⁶ , 2 doses= 600x10 ⁶	24	24 months		Recruiting	Yes	2023	18-75